Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-CURE: Dostarlimab for resectable dMMR/MSI-H solid tumors
jRCT2031250364Recruiting
- Sponsor
- GSK
- Start
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of dostarlimab in Nonhematologic neoplasms, sponsored by GSK. Primary endpoint: 12-month cCR rate. Started Feb 2026; status: recruiting.
02
Drugs
dostarlimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031250364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250364.